Mims, A., Wei, L., McLaughlin, E., Jain, J., Zeidner, J., Odenike, O., Venugopal, S., Blachly, J., Duong, V., Patel, A., Eisenmann, E., Orwick, S., Buelow, D., Behbehani, G., Little, R., Gore, S., Baker, S. (2025). Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged Acute Myeloid Leukemia: Preliminary results from the Phase 1b etctn 10596 study. Blood. https://doi.org/10.1182/blood-2025-5206